SEROLOGICAL MARKERS IN SYSTEMIC SCLERODERMA: CLINICAL CORRELATIONS AND DIAGNOSTIC IMPORTANCE

Authors

  • Graciele Ferreira dos Santos Autor
  • Fernando Vianna Cabral Pucci Autor

DOI:

https://doi.org/10.63330/armv1n9-044

Keywords:

Systemic scleroderma, Autoantibodies, Serological markers, Diagnosis, Clinical manifestations

Abstract

Systemic scleroderma (SSc) is a rare autoimmune disease characterized by progressive fibrosis of the skin and internal organs, vasculopathy, and abnormal immune activation. Serological markers are essential for diagnosis, classification, and prognosis, helping to confirm the diagnosis, identify clinical subtypes, and correlate with organ involvement. METHODOLOGY: Based on an integrative review conducted from August to November 2025 of national and international scientific articles published between 2011 and 2025. The research used the following descriptors from the Health Sciences Descriptors (DeCS) search: “Systemic scleroderma,” “Autoantibodies,” “Serological markers,” “Early diagnosis,” “Clinical manifestations,” which were combined with the Boolean connector “AND/OR.” RESULTS: After applying the exclusion criteria, ten articles were selected for analysis, indicating that autoantibodies are useful in diagnosis and predictive of clinical evolution, risk of severe complications, and the need for individualized follow-up. DISCUSSION: Studies have shown that anti-RNAP III is a significant marker for identifying patients with scleroderma with a more aggressive clinical course, associated with a high risk of renal crisis. Anti-Scl-70 is linked to greater skin fibrosis, pulmonary impairment, and progression of interstitial lung disease. In general, autoantibodies help predict disease progression, anticipate complications, and guide individualized treatments, consolidating serology as an essential tool in the management of SSc. CONCLUSION: The study concludes that it is essential to expand knowledge about SSc serological markers and their correlation with clinical manifestations. The findings reinforce the potential of these markers to improve diagnostic criteria, promote early diagnosis, and guide individualized patient management. Furthermore, the importance of promoting new research that deepens these relationships in the context of the Brazilian population is emphasized.

Downloads

Download data is not yet available.

References

BAIRKDAR, Majd; ROSSIDES, Marios; WESTERLIND, Helga; HESSELSTRAND, Roger; ARKEMA, Elizabeth V.; HOLMQVIST, Marie. Incidência e prevalência de esclerose sistêmica globalmente: uma revisão sistemática abrangente e meta-análise. Rheumatology, v. 60, n. 7, p. 3121–3133, jul. 2021. DOI: https://doi.org/10.1093/rheumatology/keab190. Acesso em: 10 nov. 2025.

CRAVO, M.; MENDONÇA, T.; FARINHA, F. Espectro clínico dos autoanticorpos TH/TO e NOR90 na esclerose sistémica. Revista Portuguesa de Medicina Interna (RPMI), v. 28, p. 140–144, 2021. Acesso em: 17 nov. 2025.

DEL GALDO, F.; LESCOAT, A.; CONAGHAN, P. G. et al. EULAR recommendations for the treatment of systemic sclerosis: 2023 update. Annals of the Rheumatic Diseases, v. 84, n. 1, p. 29–40, 2025. DOI: 10.1136/ard-2024-226430. Acesso em: 04 nov. 2025.

DEL RIO, A. P.; SACHETTO, Z.; SAMPAIO-BARROS, P. D.; MARQUES-NETO, J. F.; LONDE, A. C.; BERTOLO, M. B. HLA markers for poor prognosis in systemic sclerosis Brazilian patients. Disease Markers, v. 35, n. 2, p. 73-78, 2013. DOI: 10.1155/2013/301415. Acesso em: 07 nov. 2025.

EL GHASSEM, M. et al. High anti-topoisomerase-1 autoantibodies levels are associated with the extension of skin fibrosis and vascular progression in patients with systemic sclerosis. [s. l.], 2023. Disponível em: PubMed. Acesso em: 20 nov. 2025.

ELHANNANI, A. et al. Anticorpos anti-RNA polimerase III na esclerose sistêmica: prevalência e associações clínicas de uma revisão sistemática e meta-análise. Rheumatology (Oxford), 2025. doi: 10.1093/rheumatology/keaf392. Acesso em: 27 nov. 2025.

ELHANNANI, A. et al. Anti-RNA polymerase III antibodies in systemic sclerosis: prevalence and clinical associations from a systematic review and meta-analysis. Rheumatology (Oxford), Oxford, 2025. Disponível em: https://doi.org/10.1093/rheumatology/kead052. Acesso em: 27 nov. 2025.

GRIGOLO, B.; MAZZETTI, I.; MELICONI, R.; BAZZI, S.; SCORZA, R.; CANDELA, M.; GABRIELLI, A.; FACCHINI, A. Anti-topoisomerase II alpha autoantibodies in systemic sclerosis: association with pulmonary hypertension and HLA-B35. Clinical and Experimental Immunology, v. 121, n. 3, p. 539-543, 2000. DOI: 10.1046/j.1365-2249.2000.01320.x. Acesso em: 21 nov. 2025.

HAMAGUCHI, Y.; TAKEHARA, K. Anti-nuclear autoantibodies in systemic sclerosis: news and perspectives. Journal of Scleroderma and Related Disorders, v. 3, n. 3, p. 201–213, 2018. DOI: 10.1177/2397198318783930. Acesso em: 20 nov. 2025.

HAMAGUCHI, Y.; TAKEHARA, K. Anti-nuclear autoantibodies in systemic sclerosis: news and perspectives. Journal of Scleroderma and Related Disorders, v. 3, n. 3, p. 201–213, 2018. DOI: 10.1177/2397198318783930. Acesso em: 20 nov. 2025.

HORIMOTO, A. M. C. et al. Incidência e prevalência de esclerose sistêmica em Campo Grande, Estado de Mato Grosso do Sul, Brasil. Revista Brasileira de Reumatologia, v. 57, n.2, p. 107–114, 2017. Acesso em: 13 nov. 2025.

JANDALI, B.; SALAZAR, G. A.; HUDSON, M.; FRITZLER, M. J.; LYONS, M. A.; ESTRADA-Y-MARTIN, R. M.; CHARLES, J.; TERRACINA, K. A.; MAYES, M. D.; ASSASSI, S. O efeito do método de determinação de anticorpos Anti-Scl-70 em seu significado preditivo para a progressão da doença pulmonar intersticial na esclerose sistêmica. ACR Open Rheumatology, v. 4, p. 345-351, 2022. Disponível em: https://doi.org/10.1002/acr2.11398. Acesso em: 20 nov. 2025.

LEROY, E. C.; MEDSGER JR, T. A. Criteria for the classification of early systemic sclerosis. The Journal of rheumatology, v. 28, n. 7, p. 1573–6, jul. 2001. Acesso em: 17 nov. 2025.

LIU, C.; HOU, Y.; XU, D.; et al. Analysis of anti-RNA polymerase III antibodies in Chinese Han systemic sclerosis patients. Clinical Rheumatology, v. 39, n. 4, p. 1191-1197,2020.DOI: 10.1007/s10067-019-04806-9. Acesso em: 17 nov. 2025.

PEREIRA, Manoela Carrera MC et al. Esclerodermia sistêmica: relato de caso clínico. Revista de Odontologia da Universidade Cidade de São Paulo, v. 21, n. 1, p. 69, 2017. Acesso em: 03 nov. 2025.

TREVISAN, Mauro; PEREIRA, Daiana Rufino; DE OLIVEIRA, Ester Florentino. Estudo sobre as principais manifestações clínicas apresentadas por paciente com esclerodermia sistêmica limitada e difusa. Revista Interdisciplinar de Estudos em Saúde, p. 118-148, 2016. Acesso em: 03 nov. 2025.

WHITTEMORE, R.; KNAFL, K. The integrative review: updated methodology. Journal of Advanced Nursing, v. 52, n. 5, p. 546-553, dez. 2005. Acesso em: 13 nov. 2025.

ZIMMERMANN, Gabriela S.; PIZZICHINI, Mário M. M. Autoanticorpos na esclerose sistêmica: implicações clínicas e laboratoriais. Revista Brasileira de Reumatologia, v. 53, n. 1, p. 91–99, 2013. Acesso em: 07 nov. 2025

Published

2025-12-02

How to Cite

SEROLOGICAL MARKERS IN SYSTEMIC SCLERODERMA: CLINICAL CORRELATIONS AND DIAGNOSTIC IMPORTANCE . (2025). Aurum Revista Multidisciplinar, 1(9), 563-573. https://doi.org/10.63330/armv1n9-044